Introduction
Minimally invasive surgery is a standard procedure for removing benign ovarian tumors, and it has become increasingly applied for the management of patients with mucinous ovarian tumors. Mucinous ovarian tumors are large, particularly among the intestinal type, and 15% of mucinous ovarian tumors are borderline mucinous ovarian tumors (mBOTs). Careful removal of the tumors without spillage of the cyst contents is crucial during surgery, particularly laparoscopy, to prevent metastasis. Although port-site metastasis is well known, it has a very low incidence. Here, we report a case of port-site metastasis after laparoscopic surgery for mBOTs without spillage and review the related literature.
Case Presentation
The patient was a 50-year-old nulligravida who presented with abdominal distension. Ultrasonography revealed a multilocular cyst in the pelvic cavity. Magnetic resonance imaging showed a 20 × 10-cm multilocular mass with various signal intensities. The wall and septa of the mass were neither thick nor enhanced. A laparoscopy was performed with insertion of a 10-mm trocar through a small incision in the umbilicus and placement of two 5-mm trocars 2 cm medial to the right anterior superior iliac spine and midline, 10 cm below the umbilical puncture. An intact left ovarian tumor was observed. Ascites was not observed. Peritoneal washing cytology was performed with negative findings. The infundibulopelvic ligament, ovarian ligament, and tube were sealed using a vessel sealing device and dissected. A Lap Disk Mini, protecting the incision area, was attached to the umbilical incision, which was widened to 2 cm. The tumor was reduced by aspiration of the cyst contents (total 500 ml) through the umbilical incision and removed through the umbilical incision without a retrieval bag. The weight of the tumor was 1,540 g. Hematoxylin and eosin-stained sections revealed atypical epithelium-containing goblet cells that resembled gastrointestinal epithelium, but stromal invasion was negative ( fig. 1 ). The final diagnosis was stage IA intestinal-type mBOT, so the patient did not undergo adjuvant therapy. Twenty-six months after surgery, the patient presented with a 3 × 5-cm palpable mass on the umbilicus. Biopsy of the mass revealed mucinous adenocarcinoma and computed tomography revealed a 3.5 × 4.0-cm mass at the umbilicus without additional metastases ( fig. 2) . A laparotomy was performed and no metastasis in the peritoneal cavity was observed by gross examination. An umbilical mass resection, hysterectomy, right salpingo-oophorectomy, appendectomy, and partial omentectomy were performed. Hematoxylin and eosin-stained sections of the umbilical mass revealed glands of varying size infiltrating the stroma, immunohistologic staining for cytokeratin 7 was positive, and cytokeratin 20 was negative, but no other metastases were observed ( fig. 3) . The patient was diagnosed with port-site metastasis and invasive recurrence of mBOT. The patient underwent six cycles of adjuvant paclitaxel and carboplatin therapy.
Discussion
Benign ovarian tumors are usually resected laparoscopically. Mucinous ovarian tumors are large, however, and mBOTs are sometimes found after surgery even if mucinous ovarian tumors are suspected to be benign based on imaging. In the present case, magnetic resonance imaging did not suggest malignancy. The mean of 97 loculi in mBOTs is much greater than the mean of 18 loculi found in benign mucinous ovarian tumors [1] . High signal intensity on T1-weighted image generally indicates hemorrhages or mucoid fluid and is visible in 52% of mBOTs [2] . The diagnostic criteria for mBOTs remain unclear. Large cysts increase the risk of rupture. Rupture of the tumor during surgery may lead to metastasis when the tumor is borderline malignant. Therefore, management of large ovarian tumors through laparotomy is preferred over laparoscopy to prevent metastasis due to rupture. A study comparing laparoscopy and laparotomy for borderline ovarian tumors [3] reported a similar incidence of metastasis between groups, but the mean tumor size was larger in the laparotomy group than in the laparoscopy group (13.5 vs. 7.5 cm, respectively), indicating that surgeons tend to select laparotomy for large tumors. To prevent spillage of the tumor contents with laparoscopy, the tumor contents should be aspirated with a laparoscopic needle, avoiding accidental penetration through the tumor, and retrieved using a bag. It is difficult to reduce mBOTs compared with serous BOTs due to the multilocularity and the high viscosity of the mBOT cyst content. When the tumor is too large to be retrieved in a bag, it should be carefully extracted through the umbilical incision without contamination by the tumor contents. In the present case, however, port-site metastasis occurred despite careful extraction of the tumor. Contamination of the forceps or laparoscopic needle might also lead to metastasis. Another measure aimed at reducing port-site metastasis is irrigation of the trocar site with sterile water or 5% povidone iodine [4] . This procedure was not used in the present case. Port-site metastasis is an uncommon complication, occurring in 1% of laparoscopic surgeries for gynecologic malignancies [5, 6] . Furthermore, there are few reports of port-site metastasis of BOTs [3] , so the incidence of port-site metastasis appears to be rarer for BOT than for ovarian cancer. The risk of progression to invasive carcinoma is very low in patients with early-stage BOTs [7, 8] . A recent report discussed a mucinous subgroup of BOT in a small 'high-risk' group that is likely to recur invasively after fertilitysparing surgery [9] .
When performing surgery for large ovarian tumors that are thought to be benign mucinous ovarian tumors based on magnetic resonance imaging, surgeons should consider the possibility of borderline malignancy. Large ovarian tumors should be carefully extracted without spillage of the tumor contents to prevent port-site metastasis, despite the low incidence. In these cases, surgeons should consider laparotomy rather than laparoscopy.
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